title: Chimeric Filoviruses for Identification and Characterization of Monoclonal Antibodies.
abstract: Recent experiments suggest that some glycoprotein (GP)-specific monoclonal antibodies (MAbs) can protect experimental animals against the filovirus Ebola virus (EBOV). There is a need for isolation of MAbs capable of neutralizing multiple filoviruses. Antibody neutralization assays for filoviruses frequently use surrogate systems such as the rhabdovirus vesicular stomatitis Indiana virus (VSV), lentiviruses or gammaretroviruses with their envelope proteins replaced with EBOV GP or pseudotyped with EBOV GP. It is optimal for both screening and in-depth characterization of newly identified neutralizing MAbs to generate recombinant filoviruses that express a reporter fluorescent protein in order to more easily monitor and quantify the infection. Our study showed that unlike neutralization-sensitive chimeric VSV, authentic filoviruses are highly resistant to neutralization by MAbs. We used reverse genetics techniques to replace EBOV GP with its counterpart from the heterologous filoviruses Bundibugyo virus (BDBV), Sudan virus, and even Marburg virus and Lloviu virus, which belong to the heterologous genera in the filovirus family. This work resulted in generation of multiple chimeric filoviruses, demonstrating the ability of filoviruses to tolerate swapping of the envelope protein. The sensitivity of chimeric filoviruses to neutralizing MAbs was similar to that of authentic biologically derived filoviruses with the same GP. Moreover, disabling the expression of the secreted GP (sGP) resulted in an increased susceptibility of an engineered virus to the BDBV52 MAb isolated from a BDBV survivor, suggesting a role for sGP in evasion of antibody neutralization in the context of a human filovirus infection.
  
  
  OBJECTIVE
  The study demonstrated that chimeric rhabdoviruses in which G protein is replaced with filovirus GP, widely used as surrogate targets for characterization of filovirus neutralizing antibodies, do not accurately predict the ability of antibodies to neutralize authentic filoviruses, which appeared to be resistant to neutralization. However, a recombinant EBOV expressing a fluorescent protein tolerated swapping of GP with counterparts from heterologous filoviruses, allowing high-throughput screening of B cell lines to isolate MAbs of any filovirus specificity. Human MAb BDBV52, which was isolated from a survivor of BDBV infection, was capable of partially neutralizing a chimeric EBOV carrying BDBV GP in which expression of sGP was disabled. In contrast, the parental virus expressing sGP was resistant to the MAb. Thus, the ability of filoviruses to tolerate swapping of GP can be used for identification of neutralizing MAbs specific to any filovirus and for the characterization of MAb specificity and mechanism of action.
authors.affiliation: Department of Pathology, University of Texas Medical Branch, Galveston, Texas, USA.|Galveston National Laboratory, Galveston, Texas, USA.
authors.forename: Philipp A
authors.initials: PA
authors.lastname: Ilinykh
authors.affiliation: Department of Pathology, University of Texas Medical Branch, Galveston, Texas, USA.|Galveston National Laboratory, Galveston, Texas, USA.
authors.forename: Xiaoli
authors.initials: X
authors.lastname: Shen
authors.affiliation: Department of Pathology, Microbiology, and Immunology, Vanderbilt University, Nashville, Tennessee, USA.
authors.forename: Andrew I
authors.initials: AI
authors.lastname: Flyak
authors.affiliation: Department of Pathology, University of Texas Medical Branch, Galveston, Texas, USA.|Galveston National Laboratory, Galveston, Texas, USA.
authors.forename: Natalia
authors.initials: N
authors.lastname: Kuzmina
authors.affiliation: Department of Pathology, University of Texas Medical Branch, Galveston, Texas, USA.|Galveston National Laboratory, Galveston, Texas, USA.
authors.forename: Thomas G
authors.initials: TG
authors.lastname: Ksiazek
authors.affiliation: Department of Pathology, Microbiology, and Immunology, Vanderbilt University, Nashville, Tennessee, USA.|Vanderbilt Vaccine Center, Vanderbilt University, Nashville, Tennessee, USA.|Department of Pediatrics, Vanderbilt University, Nashville, Tennessee, USA.
authors.forename: James E
authors.initials: JE
authors.lastname: Crowe
authors.affiliation: Department of Pathology, University of Texas Medical Branch, Galveston, Texas, USA alexander.bukreyev@utmb.edu.|Galveston National Laboratory, Galveston, Texas, USA.
authors.forename: Alexander
authors.initials: A
authors.lastname: Bukreyev
mesh_terms: D000818:Animals; D000911:Antibodies, Monoclonal / Q000276:immunology*; D057134:Antibodies, Neutralizing / Q000276:immunology; D000914:Antibodies, Viral / Q000276:immunology*; D002522:Chlorocebus aethiops; D016563:Filoviridae / Q000235:genetics / Q000276:immunology*; D006801:Humans; D011994:Recombinant Proteins / Q000235:genetics / Q000276:immunology; D059386:Reverse Genetics; D014709:Vero Cells; D014759:Viral Envelope Proteins / Q000235:genetics / Q000276:immunology
chemical_list: D000911:Antibodies, Monoclonal; D057134:Antibodies, Neutralizing; D000914:Antibodies, Viral; D011994:Recombinant Proteins; D014759:Viral Envelope Proteins
references.citation: Cell. 2015 Feb 26;160(5):893-903
references.pmid: 25723164
references.citation: Sci Rep. 2014;4:6881
references.pmid: 25375093
references.citation: J Virol. 2015 Aug;89(15):7567-83
references.pmid: 25972536
references.citation: J Infect Dis. 2015 Oct 1;212 Suppl 2:S226-33
references.pmid: 26138826
references.citation: Cell. 2016 Jan 28;164(3):392-405
references.pmid: 26806128
references.citation: Nature. 2008 Jul 10;454(7201):177-82
references.pmid: 18615077
references.citation: Mol Biol Evol. 2008 Aug;25(8):1619-30
references.pmid: 18463089
references.citation: PLoS Pathog. 2008 Nov;4(11):e1000212
references.pmid: 19023410
references.citation: J Virol. 2008 Dec;82(24):12191-204
references.pmid: 18842713
references.citation: Virology. 2000 Mar 1;268(1):1-6
references.pmid: 10683320
references.citation: J Virol. 2002 Jun;76(12):6408-12
references.pmid: 12021376
references.citation: J Virol. 2004 May;78(10):5458-65
references.pmid: 15113924
references.citation: J Virol. 2004 Jul;78(14):7344-51
references.pmid: 15220407
references.citation: J Bacteriol. 1966 Feb;91(2):803-12
references.pmid: 4286889
references.citation: J Virol. 1993 Mar;67(3):1203-10
references.pmid: 8437211
references.citation: FEBS Lett. 1993 May 24;323(1-2):183-7
references.pmid: 8495737
references.citation: Virus Res. 1993 Sep;29(3):215-40
references.pmid: 8237108
references.citation: Virology. 1995 Dec 20;214(2):421-30
references.pmid: 8553543
references.citation: Proc Natl Acad Sci U S A. 1996 Apr 16;93(8):3602-7
references.pmid: 8622982
references.citation: Virology. 1997 Dec 8;239(1):206-16
references.pmid: 9426460
references.citation: J Virol. 1998 Apr;72(4):3155-60
references.pmid: 9525641
references.citation: Proc Natl Acad Sci U S A. 1998 May 12;95(10):5762-7
references.pmid: 9576958
references.citation: J Virol. 1999 Jul;73(7):6024-30
references.pmid: 10364354
references.citation: Virology. 2005 Feb 5;332(1):20-7
references.pmid: 15661137
references.citation: J Biol Chem. 2006 Jun 9;281(23):15951-8
references.pmid: 16595665
references.citation: PLoS Med. 2006 Jun;3(6):e177
references.pmid: 16683867
references.citation: N Engl J Med. 2006 Aug 31;355(9):909-19
references.pmid: 16943403
references.citation: Vaccine. 2007 Jan 22;25(6):993-9
references.pmid: 17055127
references.citation: J Virol. 2007 Apr;81(8):3942-8
references.pmid: 17267489
references.citation: Virus Res. 2008 Sep;136(1-2):81-90
references.pmid: 18514350
references.citation: PLoS Pathog. 2009 Jul;5(7):e1000536
references.pmid: 19649327
references.citation: MMWR Morb Mortal Wkly Rep. 2009 Dec 18;58(49):1377-81
references.pmid: 20019654
references.citation: Virology. 2010 Jun 5;401(2):228-35
references.pmid: 20304456
references.citation: J Virol. 2011 Jun;85(11):5406-14
references.pmid: 21411529
references.citation: J Virol. 2011 Aug;85(16):8188-96
references.pmid: 21680524
references.citation: J Infect Dis. 2011 Nov;204 Suppl 3:S776-84
references.pmid: 21987750
references.citation: PLoS Pathog. 2011 Oct;7(10):e1002304
references.pmid: 22039362
references.citation: Proc Natl Acad Sci U S A. 2012 Mar 13;109(11):4275-80
references.pmid: 22371572
references.citation: Proc Natl Acad Sci U S A. 2012 Mar 27;109(13):5034-9
references.pmid: 22411795
references.citation: Sci Transl Med. 2012 Jun 13;4(138):138ra81
references.pmid: 22700957
references.citation: PLoS Pathog. 2012;8(8):e1002847
references.pmid: 22876185
references.citation: Proc Natl Acad Sci U S A. 2012 Oct 30;109(44):18030-5
references.pmid: 23071322
references.citation: J Virol. 2012 Dec;86(24):13467-74
references.pmid: 23035224
references.citation: PLoS Pathog. 2012;8(12):e1003065
references.pmid: 23271969
references.citation: Arch Virol. 2013 Jan;158(1):301-11
references.pmid: 23001720
references.citation: J Virol. 2013 Jul;87(13):7471-85
references.pmid: 23616668
references.citation: J Virol. 2014 Jan;88(1):99-109
references.pmid: 24131711
references.citation: Arch Virol. 2014 May;159(5):1229-37
references.pmid: 24190508
references.citation: Nature. 2014 Oct 2;514(7520):47-53
references.pmid: 25171469
references.citation: Microbiol Spectr. 2015 Feb;3(1):AID-0027-2014
references.pmid: 26104564